Menu Search
Equities

Nutriband Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
9WV:FRA

Nutriband Inc

Actions
  • Price (EUR)3.36
  • Today's Change0.08 / 2.44%
  • Shares traded999.00
  • 1 Year change-48.31%
  • Beta1.7843
Data delayed at least 15 minutes, as of Feb 11 2026 07:05 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

  • Revenue in USD (TTM)2.28m
  • Net income in USD-34.59m
  • Incorporated2016
  • Employees13.00
  • Location
    Nutriband Inc121 S Orange Ave Ste 1500ORLANDO 32801-3241United StatesUSA
  • Phone+1 (407) 377-6695
  • Websitehttps://nutriband.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.